AnaptysBio Q2 2024 Adj EPS $(1.71) Misses $(0.89) Estimate, Sales $11.00M Miss $24.30M Estimate
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio (NASDAQ:ANAB) reported Q2 2024 adjusted EPS of $(1.71), missing the $(0.89) estimate by 92.13%. Sales were $11.00M, missing the $24.30M estimate by 54.73%. Despite the misses, sales increased by 217.92% from $3.46M last year.
August 05, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AnaptysBio reported significant misses in both EPS and sales for Q2 2024, with EPS missing by 92.13% and sales missing by 54.73%. Despite the misses, sales increased by 217.92% year-over-year.
The significant misses in both EPS and sales are likely to negatively impact the stock price in the short term. However, the substantial year-over-year sales increase may provide some support.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100